| Bioactivity | GS-9822 is a potent antivira agent with nanomolar activity against wild-type HIV-1 viruses. GS-9822 potently inhibits the LEDGF/p75-integrase interaction with an IC50 of 0.07 μM. GS-9822 has high in vitro metabolic stability and favorable oral pharmacokinetic profiles with low systemic clearance in rats, dogs, and monkeys[1]. |
| Target | EC50: 0.0022 μM (Strain IIIb), 0.0025 μM (Strain NL4.3)IC50: 0.07 μM (LEDGF/p75-integrase) |
| Name | GS-9822 |
| CAS | 2219362-41-9 |
| Formula | C36H39ClN4O4S |
| Molar Mass | 659.24 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bruggemans A, et al. GS-9822, a preclinical LEDGIN candidate, displays a block-and-lock phenotype in cell culture. Antimicrob Agents Chemother. 2023 May 1;65(5):e02328-20. |
GS-9822
CAS: 2219362-41-9 F: C36H39ClN4O4S W: 659.24
GS-9822 is a potent antivira agent with nanomolar activity against wild-type HIV-1 viruses. GS-9822 potently inhibits th
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.